PSMA-directed CAR T cells combined with low-dose docetaxel treatment induce tumor regression in a prostate cancer xenograft model
Alzubi J, Dettmer-Monaco V, Kuehle J, Thorausch N, Seidl M, Taromi S, Schamel W, Zeiser R, Abken H, Cathomen T, Wolf P.
The design and subsequent engineering of synthetic proteins is one area of the excellence cluster. One prime examples are chimeric antigen receptors (CARs) that are used in the clinics for cancer immunotherapy. In this cooperative publication we contributed to the characterization of two novel CARs developed by the groups of Toni Cathomen and Philipp Wolf. These CARs are directed against human prostate cancer and contain different signalling domains at the cytoplasmic tails.